Clinical trials: Vasculitis
Kawasaki Disease
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT04747847
- Testing
- Atorvastatin and anakinra
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Kawasaki Disease
Infliximab (Remicade) for Patients With Acute Kawasaki Disease
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.
- Trial name
- NCT00271570
- Testing
- Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Diego
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi
Vasculitis
Hematopoietic Stem Cell Support in Vasculitis
The systemic vasculitis is a wide-ranging group of diseases that are characterized by the presence of blood vessel inflammation (1).
- Trial name
- NCT00278512
- Testing
- Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Kawasaki Disease
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.
- Trial name
- NCT00162032
- Testing
- Sestamibi
- Where
- 50 sites in United States, Brazil and 5 more
- Volunteers
- 445 people
- Sponsor
- Lantheus Medical Imaging
Giant Cell Arteritis, Temporal Arteritis
Ustekinumab for the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Horton's Disease
- Trial name
- UGCA (NCT02955147)
- Testing
- Ustekinumab, Prednisone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Wegener's Granulomatosis
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys.
- Trial name
- NCT00468208
- Testing
- Abatacept
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Autoimmune Connective Tissue Disorder, Immune System Diseases
Anakinra for Behcet s Disease
Background: Behcet's disease (BD) is an autoimmune disease where the immune system attacks the body. People with BD may develop oral or genital ulcers, skin problems, and eye disease.
- Trial name
- NCT01441076
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Uveitis, Intermediate Uveitis
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT01789320
- Testing
- triamcinolone acetonide (Triesence®)
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Clearside Biomedical, Inc.
Vasculitis
Belimumab in Remission of VASculitis
The purpose of this study is to evaluate the efficacy and safety of belimumab, in combination with azathioprine, for the maintenance of remission following a standard induction regimen in patients with Wegener's granulomatosis or…
- Trial name
- BREVAS (NCT01663623)
- Testing
- Belimumab 10 mg/kg, Azathioprine
- Where
- 89 sites in United States, Australia and 18 more
- Volunteers
- 106 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Giant Cell Arteritis
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA.
- Trial name
- NCT01791153
- Testing
- Tocilizumab, Prednisone, Corticosteroids
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Hoffmann-La Roche
Giant Cell Arteritis
Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant cell arteritis (GCA or temporal arteritis or cranial arteritis) or Horton disease is a vasculitis that occurs in older adults, affecting vessels of medium and large caliber.
- Trial name
- ECHORTON (NCT02703922)
- Testing
- color Doppler ultrasound and TAB in case of CDU negative
- Where
- 6 sites in France
- Volunteers
- 165 people
- Sponsor
- Poitiers University Hospital
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy…
- Trial name
- NCT01596335
- Testing
- TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Giant Cell Arteritis
Tocilizumab for Patients With Giant Cell Arteritis
Giant-cell arteritis (GCA) is an immune-mediated disease that mostly affects people older than 50 years of age. Glucocorticoid (GC) treatment dramatically alters the symptoms and course of GCA, reducing the likelihood of vascular…
- Trial name
- NCT01450137
- Testing
- Tocilizumab + Glucocorticoids (GCs)
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Trial name
- IXchange (NCT03895801)
- Testing
- IFX-1, Glucocorticoid (GC)
- Where
- 76 sites in Belgium, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- InflaRx GmbH
Arteritis, Giant Cell
Baricitinib in Relapsing Giant Cell Arteritis
This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study.
- Trial name
- NCT03026504
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Matthew J Koster
Churg-Strauss Syndrome
Rituxan in Churg Strauss Syndrome With Renal Involvement
Churg-Strauss Syndrome (CSS) is a disease characterized by asthma, abnormally high amounts of eosinophils (a type of white blood cell), and blood vessel inflammation. About 25% of CSS patients develop kidney disease.
- Trial name
- NCT00424749
- Testing
- Rituximab, Prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fernando Fervenza
Kawasaki Disease
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
- Trial name
- NCT00760435
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- University of California, San Diego
Takayasu Arteritis
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).
- Trial name
- NCT04882072
- Testing
- Ustekinumab, Glucorticoid Taper Regimen
- Where
- 27 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Janssen Pharmaceutical K.K.
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline